These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 27206283)

  • 41. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian study.
    Uccella S; Falcone F; Greggi S; Fanfani F; De Iaco P; Corrado G; Ceccaroni M; Mandato VD; Bogliolo S; Casarin J; Monterossi G; Pinelli C; Mangili G; Cormio G; Roviglione G; Bergamini A; Pesci A; Frigerio L; Uccella S; Vizza E; Scambia G; Ghezzi F
    J Gynecol Oncol; 2018 Nov; 29(6):e100. PubMed ID: 30207108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan.
    Lee YY; Lai YL; Kim MS; Chang K; Kim HS; Cheng WF; Chen YL
    J Gynecol Oncol; 2024 May; 35(3):e33. PubMed ID: 38130137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center.
    Kato MK; Yoshida H; Uehara T; Uno M; Ishikawa M; Miyasaka N; Kato T
    Taiwan J Obstet Gynecol; 2021 Mar; 60(2):238-244. PubMed ID: 33678322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiation therapy improves disease-specific survival in women with Stage II endometrioid endometrial cancer-Brachytherapy may be sufficient.
    Nwachukwu CR; Von-Eyben R; Kidd EA
    Brachytherapy; 2018; 17(2):383-391. PubMed ID: 29198879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does Age-Adjusted Charlson Comorbidity Score Impact Survival Endpoints in Women with Federation of Gynecology and Obstetrics-Stage III Endometrial Cancer?
    Ghanem AI; Modh A; Burmeister C; Munkarah AR; Elshaikh MA
    Gynecol Obstet Invest; 2018; 83(3):290-298. PubMed ID: 29518778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
    Bhatnagar AR; Ghanem AI; Alkamachi B; Allo G; Lin CH; Hijaz M; Elshaikh MA
    Gynecol Oncol; 2024 Sep; 188():44-51. PubMed ID: 38936280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multi-institutional analysis of sequential versus 'sandwich' adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma.
    Onal C; Sari SY; Yildirim BA; Yavas G; Gultekin M; Guler OC; Akyurek S; Yildiz F
    J Gynecol Oncol; 2019 May; 30(3):e28. PubMed ID: 30887753
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
    Alektiar KM; McKee A; Lin O; Venkatraman E; Zelefsky MJ; McKee B; Hoskins WJ; Barakat RR
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):79-85. PubMed ID: 12182977
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival analysis of endometrial cancer patients with positive lymph nodes.
    Brown AP; Gaffney DK; Dodson MK; Soisson AP; Belnap TW; Alleman K; Sause WT
    Int J Gynecol Cancer; 2013 Jun; 23(5):861-8. PubMed ID: 23598890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant radiation therapy for patients with type II endometrial carcinoma: impact on tumor recurrence and survival.
    Yechieli R; Rasool N; Robbins JR; Cogan CM; Elshaikh MA
    Int J Gynecol Cancer; 2013 May; 23(4):763-8. PubMed ID: 23485931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
    Panggid K; Cheewakriangkrai C; Khunamornpong S; Siriaunkgul S
    J Obstet Gynaecol Res; 2010 Oct; 36(5):1044-8. PubMed ID: 21058438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of lymphadenectomy on survival endpoints in women with early stage uterine endometrioid carcinoma: A matched analysis.
    Ghanem AI; Khan NT; Mahan M; Ibrahim A; Buekers T; Elshaikh MA
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():225-230. PubMed ID: 28068595
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.
    Long KC; Zhou Q; Hensley ML; Alektiar KM; Gomez J; Gardner GJ; Chi DS; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2012 Apr; 125(1):99-102. PubMed ID: 22112609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of patients with stage IIIC endometrial cancer.
    Turan T; Ureyen I; Duzguner I; Ozkaya E; Tasci T; Karalok A; Boran N; Kose MF; Tulunay G
    Int J Gynecol Cancer; 2014 Jul; 24(6):1033-41. PubMed ID: 24905617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early-stage Uterine Pure and Mixed Clear Cell Carcinoma: Outcomes and Recurrence With and Without Adjuvant Therapy.
    Chang-Halpenny CN; Natarajan S; Hwang-Graziano JM
    Am J Clin Oncol; 2018 Apr; 41(4):371-378. PubMed ID: 26950465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Xiang M; English DP; Kidd EA
    Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study.
    Ørtoft G; Lausten-Thomsen L; Høgdall C; Hansen ES; Dueholm M
    J Gynecol Oncol; 2019 Sep; 30(5):e84. PubMed ID: 31328462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.